Adage Capital Management
Adage Capital is a Boston-based hedge fund founded by Phillip Gross which held nearly $24 billion in securities at the end of the quarter ended September 30, 2010.
The firm focuses on managing S&P 500 assets predominantly for Endowments and Foundations such as Harvard University, Northwestern University, Dartmouth College, the American Red Cross and the Getty Foundation.
The firm focuses on managing S&P 500 assets predominantly for Endowments and Foundations such as Harvard University, Northwestern University, Dartmouth College, the American Red Cross and the Getty Foundation.
View Older Stories View More Recent Stories
-
Form SCHEDULE 13G Blue Water Acquisition Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Bleichroeder Acquisition Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Metropolitan Bank Holdin Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Averin Capital Acquisiti Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A MeiraGTx Holdings plc Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A INOVIO PHARMACEUTICALS, Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A HERON THERAPEUTICS, INC. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Atara Biotherapeutics, Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A EyePoint, Inc. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Armada Acquisition Corp. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Archimedes Tech SPAC Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Aldabra 4 Liquidity Oppo Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A DBV Technologies S.A. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Centessa Pharmaceuticals Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Abony Acquisition Corp. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Adagio Medical Holdings, Filed by: Adage Capital Management, L.P.
-
Artiva Biotherapeutics prices $300 million stock and warrant offering
-
Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
-
Parabilis Medicines Appoints Biopharmaceutical Finance Leader Alan M. Sebulsky to Board of Directors
-
Cabaletta Bio prices $150 million stock offering at $2.90 per share
-
Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering
-
Climb Bio raises $110 million in private placement
-
Climb Bio, Inc. Announces $110.0 Million Private Placement
-
4BIO Capital portfolio company Ray Therapeutics announces upsized and oversubscribed $125 Million Series B financing for vision restoration treatments
-
Ray Therapeutics Announces Upsized and Oversubscribed $125 Million Series B Financing for Vision Restoration Treatments
-
UNCF Announces Winners of Sixth Annual HBCU Stock Pitch Competition
-
SCYNEXIS raises $40 million in private placement financing
-
SCYNEXIS Announces $40.0 Million Private Placement
-
First Tracks Biotherapeutics secures $145 million private placement ahead of spinoff
-
AnaptysBio board approves First Tracks Biotherapeutics spin-off
-
Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics
-
First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement
-
OnKure raises $150 million to advance cancer treatment programs
-
OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies
-
Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights
-
UNCF NEW ENGLAND Raises Record-Breaking $800,000 for HBCUs and Student Success
-
Ovid Therapeutics prices $60 million private placement for drug development
-
Ovid Therapeutics Announces Pricing of $60 Million Private Placement
-
Relmada Therapeutics raises $160 million in oversubscribed private placement
-
Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing
-
Tiger Global, Adage Capital trimmed stakes in AI heavyweights in Q4
-
Form 13F-HR ADAGE CAPITAL PARTNERS For: Dec 31
-
Form 13F-NT Adage Capital Management For: Dec 31
-
Opus Genetics raises $25 million in private placement
-
Opus Genetics Announces $25 Million Private Placement
-
Form SCHEDULE 13G Vine Hill Capital Invest Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G SilverBox Corp V Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Terns Pharmaceuticals, Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Praxis Precision Medicin Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Twelve Seas Investment Filed by: Adage Capital Management, L.P.

